Animal Models of Carcinogenesis in Inflamed Colorectum: Potential Use in Chemoprevention Study

Current Drug Targets

Volumn 13, Issue 14, 2012, Pages 1689-1697

  Tanaka, Takuji ^a,b  

^a Tohkai Cytopathology Institute: Cancer Research and Prevention   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Animal model; Chemoprevention; Colorectal cancer; Inflammation and cancer; Inflammatory bowel disease

Indexed keywords

2 DEOXYRIBOSE; ACETYLSALICYLIC ACID; ASTAXANTHIN; AURAPTENE; BEZAFIBRATE; BROSTALLICIN; BROXURIDINE; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CURCUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPOTHILONE B; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IDOXURIDINE; IRINOTECAN; LOMUSTINE; MESALAZINE; METHOTREXATE; MITOMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIMESULIDE; OXALIPLATIN; PITAVASTATIN; TROGLITAZONE; UNINDEXED DRUG; VACCINE; VASCULOTROPIN INHIBITOR;

ABERRANT CRYPT FOCUS; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CROHN DISEASE; DRUG EXPOSURE; EXPERIMENTAL MODEL; HUMAN; INFLAMMATION; NONHUMAN; PRECANCER; TUMOR MODEL; ULCERATIVE COLITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84879320179     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012804545452     Document Type: Article

References (80)

1. Tanaka, T. Effect of diet on human carcinogenesis. Crit Rev Oncol Hematol 1997; 25: 73-95.
2. Tanaka T, Tanaka M, Ishigamori R. Biomarkers for colorectal cancer. Int J Mol Sci 2010; 11: 3209-3225.
3. Tanaka T. Chemoprevention of human cancer: biology and therapy. Crit Rev Oncol Hematol 1997; 25: 139-174.
4. Tanaka T. Cancer chemoprevention. Cancer J 1992; 5: 11-16.
5. Tanaka T, Shnimizu M, Moriwaki H. Cancer chemoprevention by carotenoids. Molecules 2012; 17: 3202-3242.
6. Tanaka T, Tanaka T, Tanaka M, Kuno T. Cancer chemoprevention by citrus pulp and juices containing high amounts of betacryptoxanthin and hesperidin. J Biomed Biotechnol 2012; 2012: 516981.
7. Weisburger JH. Worldwide prevention of cancer and other chronic diseases based on knowledge of mechanisms. Mutat Res 1998; 402: 331-337.
8. Mehta RG, Murillo G, Naithani R, Peng X. Cancer chemoprevention by natural products: how far have we come? Pharm Res 2010; 27: 950-961.
9. Tanaka T, Oyama T, Yasui Y. Dietary supplements and colorectal cancer. Curr Topics Neutraceut Res 2008; 6: 165-188.
10. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976; 35: 1332-1338.
11. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010; 102: 14-25.
12. Ferrari N, Tosetti F, De Flora S, et al. Diet-derived phytochemicals: from cancer chemoprevention to cardio-oncological prevention. Curr Drug Targets 2011; 12: 1909-1924.
13. Saldanha SN, Tollefsbol TO. The role of nutraceuticals in chemoprevention and chemotherapy and their clinical outcomes. J Oncol 2012; 2012: 192464.
14. Corpet DE, Pierre F. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003; 12: 391-400.
15. Corpet DE, Tache S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002; 43: 1-21.
16. Tanaka T, Ishigamori R. Understanding carcinogenesis for fighting oral cancer. J Oncol 2011; 2011: 603740.
17. Tanaka T, Miyazawa K, Tsukamoto T, Kuno T, Suzuki K. Pathobiology and chemoprevention of bladder cancer. J Oncol 2011; 2011: 528353.
18. Tanaka T, Tanaka M, Tanaka T. Oral carcinogenesis and oral cancer chemoprevention: a review. Pathol Res Int 2011; 2011: 431246.
19. Oyama T, Yasui Y, Tanaka T. Breast cancer chemoprevention: current perspectives. Curr Enzyme Inhibition 2009; 5: 198-208.
20. Bruce WR. Counterpoint: From animal models to prevention of colon cancer. Criteria for proceeding from preclinical studies and choice of models for prevention studies. Cancer Epidemiol Biomarkers Prev 2003; 12: 401-404.
21. Carroll C, Booth A, Cooper K. A worked example of best fit framework synthesis: a systematic review of views concerning the taking of some potential chemopreventive agents. BMC Med Res Methodol 2011; 11: 29.
22. Cooper K, Squires H, Carroll C, et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2010; 14: 1-206.
23. Shimizu M, Kubota M, Tanaka T, Moriwaki H. Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. Int J Mol Sci 2012; 13: 579-595.
24. Tanaka T. Development of an Inflammation-Associated Colorectal Cancer Model and Its Application for Research on Carcinogenesis and Chemoprevention. Int J Inflamm 2012; 2012: 658786.
25. Tanaka T, Hosokawa M, Yasui Y, Ishigamori R, Miyashita K. Cancer chemopreventive ability of conjugated linolenic acids. Int J Mol Sci 2011; 12: 7495-7409.
26. Tanaka T, Tanaka T, Tanaka M. Potential cancer chemopreventive activity of protocatechuic acid. J Exp Clin Med 2011; 3: 27-33.
27. Tanaka T, Yasui Y, Ishigamori-Suzuki, R Oyama T. Citrus compounds inhibit inflammation-and obesity-related colon carcinogenesis in mice. Nutr Cancer 2008; 60 Suppl 1: 70-80.
28. Sung JJ, Lau JY, Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005; 6: 871-876.
29. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003; 94: 965-973.
30. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-5345.
31. Tanaka T, Suzuki R. Inflammation and cancer. In: Tanaka, T., editor. Cancer: Disease progression and Chemoprevention 2007. Kerala (India): Research Signpost: 2007. pp. 27-44.
32. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-1315.
33. Gonzalez CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer 2012; 130: 745-753.
34. Tatematsu M, Tsukamoto T, Toyoda T. Effects of eradication of Helicobacter pylori on gastric carcinogenesis in experimental models. J Gastroenterol 2007; 42 Suppl 17: 7-9.
35. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535.
36. Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 2008; 14: 3937-3947.
37. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18 Suppl 2: 1-5.
38. Tanaka T, Kohno H, Murakami M, Shimada R, Kagami S. Colitisrelated rat colon carcinogenesis induced by 1-hydroxyanthraquinone and methylazoxymethanol acetate (Review). Oncol Rep 2000; 7: 501-508.
39. Waldner MJ, Neurath MF. Chemically induced mouse models of colitis. Curr Protoc Pharmacol 2009; Chapter 5: Unit 5 55.
40. Rosenberg DW, Giardina C, Tanaka T. Mouse models for the study of colon carcinogenesis. Carcinogenesis 2009; 30: 183-196.
41. Tanaka T. Colorectal carcinogenesis: Review of human and experimental animal studies. J Carcinog 2009; 8: 5.
42. Tanaka T, Sugie S. Inhibition of colon carcinogenesis by dietary non-nutritive compounds. J Toxicol Pathol 2007; 20: 215-235.
43. Tanaka T. Preclinical cancer chemoprevention studies using animal model of inflammation-associated colorectal carcinogenesis. Cancers 2012; 4: 673-700.
44. Suzuki R, Miyamoto S, Yasui Y, Sugie S, Tanaka T. Global gene expression analysis of the mouse colonic mucosa treated with azoxymethane and dextran sodium sulfate. BMC Cancer 2007; 7: 84.
45. Yasui Y, Tanaka T. Protein expression analysis of inflammationrelated colon carcinogenesis. J Carcinog 2009; 8: 10.
46. Suzuki R, Kohno H, Sugie S, Nakagama H, Tanaka T. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis 2006; 27: 162-169.
47. Suzuki R, Kohno H, Sugie S, Tanaka T. Sequential observations on the occurrence of preneoplastic and neoplastic lesions in mouse colon treated with azoxymethane and dextran sodium sulfate. Cancer Sci 2004; 95: 721-727.
48. Suzuki R, Kohno H, Sugie S, Tanaka T. Dose-dependent promoting effect of dextran sodium sulfate on mouse colon carcinogenesis initiated with azoxymethane. Histol Histopathol 2005; 20: 483-492.
49. Nakanishi M, Tazawa H, Tsuchiya N, Sugimura T, Tanaka T, Nakagama, H. Mouse strain differences in inflammatory responses of colonic mucosa induced by dextran sulfate sodium cause differential susceptibility to PhIP-induced large bowel carcinogenesis. Cancer Sci 2007; 98: 1157-1163.
50. Tanaka T, Suzuki R, Kohno H, Sugie S, Takahashi M, Wakabayashi K. Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess beta-catenin gene mutations and increases immunoreactivity for beta-catenin, cyclooxygenase-2 and inducible nitric oxide synthase. Carcinogenesis 2005; 26: 229-238.
51. Kohno H, Suzuki R, Sugie S, Tanaka T. Beta-Catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sodium sulfate. Cancer Sci 2005; 96: 69-76.
52. Tanaka T, Yasui Y, Tanaka M, Oyama T, Rahman KM. Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. Chem Biol Interact 2009; 177: 128-136.
53. Yoshimi K, Tanaka T, Takizawa A, et al. Enhanced colitisassociated colon carcinogenesis in a novel Apc mutant rat. Cancer Sci 2009; 100: 2022-207.
54. Toyoda-Hokaiwado N, Yasui Y, Muramatsu M, et al. Chemopreventive effects of silymarin against 1,2-dimethylhydrazine plus dextran sodium sulfate-induced inflammation-associated carcinogenicity and genotoxicity in the colon of gpt delta rats. Carcinogenesis 2011; 32: 1512-1517.
55. Hata K, Tanaka T, Kohno H, et al. Lack of enhancing effects of degraded lambda-carrageenan on the development of beta-cateninaccumulated crypts in male DBA/2J mice initiated with azoxymethane. Cancer Lett 2006; 238: 69-75.
56. Kohno H, Totsuka Y, Yasui Y, et al. Tumor-initiating potency of a novel heterocyclic amine, aminophenylnorharman in mouse colonic carcinogenesis model. Int J Cancer 2007; 121: 1659-1664.
57. Kohno H, Suzuki R, Sugie S, Tanaka T. Suppression of colitisrelated mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 2005; 5: 46.
58. Kohno H, Takahashi M, Yasui Y, et al. A specific inducible nitric oxide synthase inhibitor, ONO-1714 attenuates inflammationrelated large bowel carcinogenesis in male Apc(Min/+) mice. Int J Cancer 2007; 121: 506-513.
59. Tanaka T, de Azevedo MB, Duran N, et al. Colorectal cancer chemoprevention by 2 beta-cyclodextrin inclusion compounds of auraptene and 4'-geranyloxyferulic acid. Int J Cancer 2010; 126: 830-840.
60. Yasui Y, Suzuki R, Miyamoto S, et al. A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis. Int J Cancer 2007; 121: 2331-2339.
61. Yasui Y, Hosokawa M, Mikami N, Miyashita K, Tanaka T. Dietary astaxanthin inhibits colitis and colitis-associated colon carcinogenesis in mice via modulation of the inflammatory cytokines. Chemico Biol Interact 2011; 193: 79-87.
62. Tanaka T, Kohno H, Suzuki R, et al. Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int J Cancer 2006; 118: 25-34.
63. Jacobs RJ, Kodach LL, Hardwick JC. The potential of statins for individualized colorectal cancer chemoprevention. Curr Drug Targets 2011; 12: 1903-1908.
64. Yasuda Y, Shimizu M, Shirakami Y, et al. Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci 2010; 101: 1701-1707.
65. Shimizu M, Yasuda Y, Sakai H, et al. Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJdb/ db obese mice. BMC Cancer 2011; 11: 281.
66. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract 2005; 59: 239-252.
67. Tanaka T, Kawamori T, Ohnishi M, et al. Suppression of azoxymethane-induced rat colon carcinogenesis by dietary administration of naturally occurring xanthophylls astaxanthin and canthaxanthin during the postinitiation phase. Carcinogenesis 1995; 16: 2957-2963.
68. Tanaka T, Makita H, Ohnishi M, Mori H, Satoh K, Hara A. Chemoprevention of rat oral carcinogenesis by naturally occurring xanthophylls, astaxanthin and canthaxanthin. Cancer Res 1995; 55: 4059-4064.
69. Tanaka T, Morishita Y, Suzui M, Kojima T, Okumura A, Mori H. Chemoprevention of mouse urinary bladder carcinogenesis by the naturally occurring carotenoid astaxanthin. Carcinogenesis 1994; 15: 15-19.
70. McCart AE, Vickaryous NK, Silver A. Apc mice: models, modifiers and mutants. Pathol Res Pract 2008; 204: 479-490.
71. Smith KD, Rodriguez-Bigas MA. Role of surgery in familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer (Lynch syndrome). Surg Oncol Clin N Am 2009; 18: 705-715.
72. Hopper JL. Application of genetics to the prevention of colorectal cancer. Recent Results Cancer Res 2005; 166: 17-33.
73. Booij KA, Mathus-Vliegen EM, Taminiau JA, et al. Evaluation of 28 years of surgical treatment of children and young adults with familial adenomatous polyposis. J Pediatr Surg 2010; 45: 525-532.
74. Niho N, Takahashi M, Kitamura T, et al. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 2003; 63: 6090-6095.
75. Mutoh M, Niho N, Wakabayashi K. Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice. Biol Chem 2006; 387: 381-385.
76. Yamada Y, Hata K, Hirose Y, et al. Microadenomatous lesions involving loss of Apc heterozygosity in the colon of adult Apc(Min/+) mice. Cancer Res 2002; 62: 6367-6370.
77. Yamada Y, Mori H. Multistep carcinogenesis of the colon in Apc(Min/+) mouse. Cancer Sci 2007; 98: 6-10.
78. Rostom A, Dube C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 146: 376-389.
79. Reddy BS, Wang CX, Kong AN, et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 2006; 66: 4542-4546.
80. Russo GL. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol 2007; 74: 533-544.